Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4602 in HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors
NCT06516926Phase 2Terminated
- Sponsor
- Hengrui
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SHR-4602 in solid tumor (3 arms), sponsored by Hengrui. Primary endpoint: Objective Response Rate at 2 years. Started Aug 2024; status: terminated.
02
Drugs
SHR-4602
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06516926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516926.